Draupnir Bio
PrivateLast Round
Seed
Jul 17, 2024
Total Funding Raised
$48.91M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Draupnir Bio is a biotechnology company that develops oral, small molecule degraders of extracellular disease-causing proteins by harnessing the natural machinery of the lysosome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Draupnir Bio Comparables
Compare Draupnir Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avilar Therapeutics | 82% | |
| Lycia Therapeutics | 79% | |
| Cullgen | 76% |
Draupnir Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 17, 2024 | ||||
| Series A | Oct 1, 2019 | ||||
| Grant | Nov 30, 2017 | ||||
| Seed | Apr 1, 2017 |
Key People
Founding team and executive leadership
Draupnir Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Novo Nordisk Foundation | Grant |
| MP Healthcare Venture Management | Seed |
| Gilde Healthcare | Seed, Series A |
| Novo Holdings | Seed |
| The Export and Investment Fund of Denmark | Seed |
| Inkef Capital | Seed, Series A |
| High-Tech Gründerfonds | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 16, 2026
Grew 25% QoQ, from 16 to 20 employees.
- Aug 22, 2026
Monthly visitors increased 40% MoM.
Recent news
Latest coverage and updates
- sells_assets_toJul 21, 2026
Draupnir Bio ApS sold assets to Samsung BioLogics Co. in the amount of $1.81B on Jul 21st '26.
Draupnir Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Draupnir Bio's valuation, stock price, and market status.
Is Draupnir Bio a public or private company?
Draupnir Bio is a private company.
What is the current stock price of Draupnir Bio?
Draupnir Bio is a private company, so its shares have no public market price. Caplight tracks Draupnir Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Draupnir Bio worth (valuation)?
Valuation information for Draupnir Bio is not publicly available.
Can I buy Draupnir Bio stock?
Draupnir Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Draupnir Bio's last funding round?
Draupnir Bio's most recent funding round was Seed on July 17, 2024.
Who are the main investors in Draupnir Bio?
Key investors in Draupnir Bio include MP Healthcare Venture Management, The Export and Investment Fund of Denmark.
Will Draupnir Bio IPO soon?
No public IPO plans have been announced for Draupnir Bio.
How can I track Draupnir Bio secondary market activity?
Caplight tracks bids, offers, and trades in Draupnir Bio's shares on secondary markets.